Stock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation

Stock Track04-22

Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.

The rally follows the company's report of a 24.4% year-over-year increase in revenue, alongside a board-approved share buyback authorization of up to 10% of its issued capital. These financial improvements signal stronger operational performance and a commitment to returning value to shareholders.

Furthermore, a significant regulatory milestone provided a major catalyst. The company's drug candidate GFH375 received a second breakthrough therapy designation, marking it as the first domestically developed KRAS G12D inhibitor monotherapy to be included in a breakthrough therapy list for pancreatic cancer, bolstering investor confidence in its pipeline prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105867730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105867730","market":"sg","top_or_hot":-1,"title":"Stock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation","media":"Stock Track","content":"<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.</p><p>The rally follows the company's report of a 24.4% year-over-year increase in revenue, alongside a board-approved share buyback authorization of up to 10% of its issued capital. These financial improvements signal stronger operational performance and a commitment to returning value to shareholders.</p><p>Furthermore, a significant regulatory milestone provided a major catalyst. The company's drug candidate GFH375 received a second breakthrough therapy designation, marking it as the first domestically developed KRAS G12D inhibitor monotherapy to be included in a breakthrough therapy list for pancreatic cancer, bolstering investor confidence in its pipeline prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-22 11:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.</p><p>The rally follows the company's report of a 24.4% year-over-year increase in revenue, alongside a board-approved share buyback authorization of up to 10% of its issued capital. These financial improvements signal stronger operational performance and a commitment to returning value to shareholders.</p><p>Furthermore, a significant regulatory milestone provided a major catalyst. The company's drug candidate GFH375 received a second breakthrough therapy designation, marking it as the first domestically developed KRAS G12D inhibitor monotherapy to be included in a breakthrough therapy list for pancreatic cancer, bolstering investor confidence in its pipeline prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1105867730","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105867730","pubTimestamp":1776829001,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.The rally follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|Genfleet Therapeutics盘中大涨5.55%营收强劲增长、回购计划、突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.The rally follows the company's report of a 24.4% year-over-year increase in revenue, alongside a board-approved share buyback authorization of up to 10% of its issued capital. These financial improvements signal stronger operational performance and a commitment to returning value to shareholders.Furthermore, a significant regulatory milestone provided a major catalyst. The company's drug candidate GFH375 received a second breakthrough therapy designation, marking it as the first domestically developed KRAS G12D inhibitor monotherapy to be included in a breakthrough therapy list for pancreatic cancer, bolstering investor confidence in its pipeline prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105867730","isCrawlerRequest":true}